These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9022408)

  • 1. [A break-through in infarct prevention. WOS (West-of-Scotland)-study confirms effectiveness of early intervention using Pravastin].
    Fortschr Med Suppl; 1996; 172():1-12. PubMed ID: 9022408
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cholesterol lowering--Quo vadis? WOS (West of Scotland)--study of pravastin--a milestone in the prevention of myocardial infarct?!].
    Fortschr Med Suppl; 1995; 170():1-7. PubMed ID: 9022407
    [No Abstract]   [Full Text] [Related]  

  • 3. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
    Klose G
    Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
    Yokoyama M; Origasa H;
    Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Coronary heart disease: grave deficiencies in secondary prevention. Almost no one is concerned with blood lipids].
    Arnheim K
    MMW Fortschr Med; 2000 Jun; 142(24):18. PubMed ID: 10895577
    [No Abstract]   [Full Text] [Related]  

  • 6. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
    Lim PO; Yee KM
    Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
    [No Abstract]   [Full Text] [Related]  

  • 7. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.
    Shepherd J
    Am J Cardiol; 1995 Sep; 76(9):113C-117C. PubMed ID: 7572679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
    Shimizu M; Koizumi J; Miyamoto S; Origasa H; Mabuchi H;
    Int J Cardiol; 2005 Mar; 99(3):395-401. PubMed ID: 15771919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins and coronary artery disease--it's the clinical endpoints that count.
    Jackson G
    Br J Clin Pract; 1997; 51(1):2-3. PubMed ID: 9158261
    [No Abstract]   [Full Text] [Related]  

  • 10. Pravastatin and coronary heart disease.
    Bloom JM
    N Engl J Med; 1999 Apr; 340(14):1116-7. PubMed ID: 10206831
    [No Abstract]   [Full Text] [Related]  

  • 11. Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS.
    Iakoubova OA; Tong CH; Chokkalingam AP; Rowland CM; Kirchgessner TG; Louie JZ; Ploughman LM; Sabatine MS; Campos H; Catanese JJ; Leong DU; Young BA; Lew D; Tsuchihashi Z; Luke MM; Packard CJ; Zerba KE; Shaw PM; Shepherd J; Devlin JJ; Sacks FM
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2763-8. PubMed ID: 17008591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pravastatin on coronary events after myocardial infarction.
    Auerbach I; Behar S; Motro M
    N Engl J Med; 1997 Mar; 336(13):962. PubMed ID: 9072702
    [No Abstract]   [Full Text] [Related]  

  • 13. In search of perverse polymorphisms.
    Rosenthal N; Schwartz RS
    N Engl J Med; 1998 Jan; 338(2):122-4. PubMed ID: 9420346
    [No Abstract]   [Full Text] [Related]  

  • 14. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
    Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
    BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    DeFilippis AP; Bansal S; Blumenthal RS
    N Engl J Med; 2008 Jan; 358(2):194; author reply 194-5. PubMed ID: 18193527
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Tsubokura M; Kami M
    N Engl J Med; 2008 Jan; 358(2):193-4; author reply 194-5. PubMed ID: 18193526
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
    Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
    Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study.
    J Am Coll Cardiol; 1999 Mar; 33(4):909-15. PubMed ID: 10091815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.
    Lowe G; Rumley A; Norrie J; Ford I; Shepherd J; Cobbe S; Macfarlane P; Packard C
    Thromb Haemost; 2000 Oct; 84(4):553-8. PubMed ID: 11057849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.